Bayer has appointed Robert LaCaze as executive vice president of the new oncology strategic business unit at the Pharmaceuticals Division of Bayer, effective February 1, 2017.
Mr. LaCaze is currently senior vice president, head of the global oncology therapeutic area within the Pharmaceuticals Division at Bayer. In his new role, Mr. LaCaze will be a member of the Pharmaceuticals Division’s executive committee which is led by Dieter Weinand, Bayer AG board member and responsible for pharmaceuticals.
Prior to joining Bayer in 2015, LaCaze was at Bristol-Myers Squibb where he held the position as senior vice president, head of product and portfolio strategy in Princeton, New Jersey. He has more than 27 years of experience in various executive roles in the pharmaceutical industry. The majority of his career has been spent in oncology with a focus on global strategy, operations, and global strategic product launches, including small molecules, biologics, and immuno-oncology.
Bayer’s new oncology strategic business unit will enable the company to strategically manage and deliver its oncology portfolio including Nexavar (sorafenib tosylate), Xofigo (radium RA-223 dichloride), and Stivarga (regorafenib) as well as its early and late-stage development candidates.
The unit will combine experimental medicine oncology, clinical pharmacology oncology, early and late project management oncology, oncology strategic regulatory affairs, and clinical development oncology. In addition, the unit will include oncology strategic marketing, oncology access and pricing, medical affairs for oncology globally, early oncology commercialization, and certain operational functions. The new unit’s operating model will support accelerated development of new cancer therapeutic options for patients.